HMGB1 and epilepsy: Elevated HMGB1 levels, particularly in patients with drug-resistant epilepsy, correlate negatively with cognitive performance while correlating positively with the number of ASM, emphasizing its significance as a potential marker for early prediction of drug resistance and impairment of cognitive function, potentially improving long-term outcomes.